title: Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits.
abstract: Pravastatin, a competitive inhibitor of hydroxymethylglutaryl CoA reductase (HMG CoA reductase) is a potent hypocholesterolemic agent in humans as well as experimental animals, including the Watanabe heritable hyperlipidemic (WHHL) rabbit, lacking low density lipoprotein (LDL) receptor activity. We studied the effect of pravastatin on several aspects of cholesterol metabolism in WHHL rabbits. Cholesterol synthesis was measured by intraperitoneal injection of radioacetate and determination of its incorporation into the nonsaponifiable lipid fraction of liver, plasma, adrenal glands and gonads. A single dose of pravastatin (25 mg/kg) caused statistically significant inhibition of hepatic cholesterol synthesis at 2, 6, 12, and 24 hours following oral administration. By 48 hours, the inhibitory effect of the drug was no longer demonstrable. The pattern of radioactivity in the plasma was similar to that in the liver. The drug had no statistically significant effect on cholesterol synthesis in adrenal glands and gonads, suggesting a selective effect on the liver. Cholesterol absorption was studied after simultaneous oral administration of [3H] cholesterol and [14C] beta-sitosterol. Pravastatin, 50 mg/kg for 10 days had no effect on fecal excretion of the radiolabelled steroids over 4 days. At 24 hours the plasma level of [14C] cholesterol was 1/3 that of control in pravastatin treated animals (p < 0.05) but did not undergo an accelerated decline over 6 days. The activity of acyl CoA: cholesterol acyltransferase (ACAT) in intestinal mucosa and the concentration of hepatic cholesterol were similar in animals treated over one year with pravastatin 50 mg/kg/day or with placebo. Our data do not allow us to make definitive conclusions about the effect of pravastatin on cholesterol absorption but are compatible with the hypothesis that the drug inhibits the hepatic synthesis as well as the assembly of cholesterol into lipoproteins.
authors.affiliation: UMDNJ-Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, New Jersey 08903-0019.
authors.forename: L F
authors.initials: LF
authors.lastname: Amorosa
authors.forename: S J
authors.initials: SJ
authors.lastname: Rozovski
authors.forename: R
authors.initials: R
authors.lastname: Ananthakrishnan
authors.forename: E
authors.initials: E
authors.lastname: Coly
authors.forename: A
authors.initials: A
authors.lastname: AlHinai
authors.forename: C
authors.initials: C
authors.lastname: Martucci
authors.forename: S H
authors.initials: SH
authors.lastname: Schneider
authors.forename: T
authors.initials: T
authors.lastname: Shimamura
authors.forename: A K
authors.initials: AK
authors.lastname: Khachadurian
mesh_terms: D000042:Absorption; D000214:Acyl Coenzyme A / Q000378:metabolism; D000818:Animals; D002784:Cholesterol / Q000096:biosynthesis / Q000378:metabolism*; D006949:Hyperlipidemias / Q000235:genetics / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000201:enzymology; D008099:Liver / Q000201:enzymology; D017035:Pravastatin / Q000494:pharmacology*; D011817:Rabbits; D002785:Sterol O-Acyltransferase / Q000378:metabolism; D013997:Time Factors
chemical_list: D000214:Acyl Coenzyme A; D002784:Cholesterol; D002785:Sterol O-Acyltransferase; D017035:Pravastatin